Anti‐CTLA‐4: Tremelimumab (75 mg flat dose, per 4 weeks for 4 doses) was administered intravenously.Anti‐PD‐L1: Durvalumab (1500 mg flat dose, per 4 weeks) was administered intravenously.Ablation: Radiofrequency or cryotherapy ablation.TACE: Patients with Barcelona Clinic Liver Cancer (BCLC) Stage B received TACE. This evidence concerns the gene CTLA4 and liver cancer.